Abstract:Lung cancer patients with the epidermal growth factor receptor (EGFR) kinase domain mutations frequently show good responses to small molecule tyrosine kinase inhibitors, including Iressa and Tarceva, in clinical studies1, 2, 3. Previous studies have demonstrated that EGFR kinase domain mutations are commonly observed in lung adenocarcinomas, never-smokers, East Asian, and females4, 5, 6, 7, 8. In contrast to caucasion females, most East Asian females do not smoke, while tobacco smoking is very common in the male population. This gender-associated tobacco usage may bias the EGFR mutation incidence in lung adenocarcinoma patients. Here we analyzed the EGFR mutation rate together with gender and smoking status in Chinese lung adenocarcinoma patients. Interestingly, our results showed a comparable rate of EGFR kinase domain mutations in lung adenocarcinomas from Chinese male and female never-smokers. We have sequenced the EGFR kinase domain using cDNA extracted from 224 lung adenocarcinomas continuously collected from September 2007 to October 2009 at Shanghai Cancer Hospital, Fudan University, with patient consent. Clinical information including age, smoking history, stage and lung tumor differentiation status is listed in Table 1. All patients were Chinese; they came from Shanghai and 10 other provinces. About 62% (139/224) of the lung adenocarcinomas were from never-smokers, and about 38% (85/224) were from ever-smokers (Table 1). Only 2 of 110 Chinese females smoked, while 83 of 114 males were ever-smokers. About 63% (142/224) of lung adenocarcinomas harbored EGFR kinase domain mutations. Without considering gender-associated tobacco usage, our data were similar to those of previous reports4, 5. EGFR kinase domain mutations tended to occur in never-smokers (75.54%) more frequently than in ever-smokers (43.53%), and female patients had a higher mutation rate of the EGFR kinase domain (75.45%) than did male patients (51.75%) (P<0.01). We then analyzed the association of EGFR kinase domain mutations with gender in never-smokers and ever-smokers separately. About 55% (46/83) of male ever-smokers had EGFR mutations (Table 1). The only two female smokers had no EGFR mutations. Interestingly, a comparable EGFR kinase domain mutation rate was found in both male never-smokers (70.97%; 22/31) and female never-smokers (76.85%; 83/108) (Table 1). These data clearly showed that gender did not influence EGFR kinase domain mutation rates in never-smoker patients with lung adenocarcinomas. The low rate of EGFR mutations in males could possibly be ascribed to the low number/percentage of male never-smoker patients with lung adenocarcinomas. Similar conclusion has been drawn using Japanese clinical samples9, 10. Although Chinese and Japanese patients are both from East Asia, it has not been conclusively demonstrated that Japanese lung cancer patients are biologically the same as Chinese lung cancer patients. Our study using 224 lung adenocarcinoma specimens mainly from eastern China extends previous studies6, 7 and corroborates the notion that gender does not play a significant role in the distribution of EGFR mutations in lung adenocarcinoma. Further studies to include other areas in China and that significantly increase the patient number will be very helpful to solidify and extend our results. The status of EGFR kinase domain mutation has been proposed as one of most important factors used for Iressa or Tarceva treatment decision-making in clinic11. Based on our findings in this study, not only Chinese female never-smokers but also male never-smokers are likely to benefit from EGFR-targeted therapy. This work was supported by the National Basic Research Program of China (No 2010CB912102), the National Natural Science Foundation of China (No 30623003, 30740084, and 30871284), the Chinese Academy of Sciences (No 2008KIP101, KSCX1-YW-22), the Science and Technology Commission of Shanghai Municipality (No 08PJ14105, 09JC1416300) and the Hundred Talents Program of the Chinese Academy of Sciences to Prof Hong-bin JI.

Epidermal Growth Factor Receptor Mutations Detected in Tumors from Chinese “never Smokers”with Lung Adenocarcinoma

Egfr Mutations and the Correlation with Gefitinib Therapy in Chinese Nsclc - A Systematic Review Based on Individual Patient Data from 5 Medical Centers in China.

Lung Cancer Molecular Epidemiology in China: Recent Trends.

Prevalence of Mutation in the Epidermal Growth Factor Receptor Gene in Chinese Patients with Non-small Cell Lung Cancer

Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine

Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non–Small Cell Lung Cancer

Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China

Lung Adenocarcinoma From East Asian Never-Smokers Is A Disease Largely Defined By Targetable Oncogenic Mutant Kinases

Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

Clinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation.

Lung Cancer In Never Smokers-The East Asian Experience

Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients.

Tyrosine Kinase Inhibitors Interstitial Pneumonitis: Diagnosis and Management.

Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma

Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers

Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib

Epidermal growth factor receptor mutations in lung cancer

Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.

EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer

Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report.